ArticleArchives of academic emergency medicine2025
Diosgenin Ameliorates Cardiac Function following Myocardial Ischemia Through Angiogenic and Anti-Fibrotic Properties; An Experimental Study.
Article in Archives of academic emergency medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Angiogenesis through restoration of blood supply to the ischemic myocardium is a pivotal process that contributes to cardiac repair and leads to improvement of myocardial function. This study was conducted to evaluate cardioprotective effects of Diosgenin against myocardial infarction (MI) with focus on angiogenesis, myocardial fibrosis, and oxidative stress. Methods: 4 groups of male Wistar rats were considered for this study: (1) sham, (2) MI, (3) MI+Vehicle and (4) MI+Diosgenin. MI model was created by occluding left anterior descending (LAD) artery for 30 minutes and reperfusion was established for 14 days by opening this artery. Diosgenin (50 mg/kg) was given orally to the rats for 21 days (from 7 days before MI induction until the end of the 14-day reperfusion period). Cardiac injury markers including troponin I, creatine kinase-MB (CK-MB), and lactate dehydrogenase (LDH) were measured using enzyme-linked immunosorbent assay (ELISA), same as cardiac stress oxidative markers (superoxide dismutase (SOD), Malondialdehyde (MDA), reduced glutathione (GSH)). Echocardiography was used to measure heart function parameters and myocardial fibrosis was assessed via a specific tissue staining named Masson׳s trichrome. Blood vessel staining kit was used to assess left ventricular angiogenesis. Results: Ischemia-reperfusion injury increased serum levels of troponin I, CK-MB and LDH, as well as cardiac malondialdehyde (MDA) and myocardial fibrosis. MI also decreased myocardial function (Ejection fraction (EF)% and Fractional shortening (FS)%) and Diosgenin treatment reversed these parameters. Capillary density as marker of angiogenesis significantly increased in all of MI groups. However, development of angiogenesis was significantly higher in Diosgenin group compared with MI group. Conclusion: Diosgenin exerts cardioprotective effects against ischemia-reperfusion injury by strengthening cardiac antioxidant defense and reducing deposition of collagen fibers. It seems that the strengthening of angiogenesis in heart tissue is one of the main mechanisms of Diosgenin to increase the heart's resistance against ischemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.